Our mission is to create products that deliver on significant unmet medical needs and through ground-breaking innovation and cutting-edge research we have developed a number of new technologies that will provide better patient outcomes.
Solvotrin’s R&D focus is on four therapeutic areas:
Iron Deficiency Anaemia / Mobilisation of Iron in Chronic Disease
Iron deficiency anaemia is caused by a lack of iron and is the most common vitamin and mineral deficiency according to the World Health Organization (WHO), iron deficiency is the top nutritional disorder in the world. Solvotrin are at a significantly advanced stage of development in providing treatment for iron deficiency anaemia associated with chronic disease.
Novel Non Steroidal, Anti-inflammatory molecules;
A novel class of non steroidal, anti-inflammatory small molecules substances have demonstrated invitro significant efficacy in inhibits T-cell migration and proliferation as well as expression of pro-inflammatory cytokines. The potential in cancer and psoriasis and has shown very promising efficacy in the Aldara mouse model. The compound is also metabolized in skin to a salicylate, a GRAS linker molecule and niacin and presents low toxicity risk.
Together with immunologists at Trinity College Dublin (TCD) Solvotrin has filed a new patent on compounds with high potential for treating mild to moderate psoriasis. This has a large, poorly served market (2-3% of the world population) where current therapies are largely based on corticosteroids with poor side effect profiles or are ineffective.
Solvotrin’s compounds specifically inhibit adaptive T-cell responses in psoriasis skin without affecting normal cells. The compound is highly effective when applied topically in animal models and has promising tolerability. It is commercially de-risked because they break down in skin and blood to substances already approved in medicine and so are unlikely to cause systemic side effects. Solvotrin plans to build on the existing technical package towards phase I trials.
Aspirin is one of the most prescribed drugs in the world and is used to prevent clotting, heart attacks, stroke and death in patients with cardiovascular disease. With 75% of patient having detectable levels of gastric bleeding there is a significant opportunity to improve this established therapy. With the goal of protecting the stomach and intestine lining we have discovered a way to achieve this through the deactivation of active Aspirin which can later be reactivated naturally by enzymes naturally present in the blood. With our patented technology we have found a way to liberate active aspirin only when it is in the bloodstream. Thus the drug maintains its therapeutic qualities, without the damaging gastrointestinal side effects. Higher doses of Aspirin required for cardo protection in Obese people and menopausal women is of particular interest.